Global Multiple Sclerosis Drugs Market Size, Share & Trends Analysis Report, By Drug Class (Immunomodulators, Immunosuppressants, and Interferons), By Route of Administration (Parenteral and Oral), Forecast (2022-2028)

The Global Multiple Sclerosis Drugs Market is anticipated to grow at a CAGR of nearly 6.1% during the forecast period (2022-2028). Multiple sclerosis is defined as an immune-mediated disease of the central nervous system. It is characterized by demyelination, inflammation, and degenerative changes such as progressive brain and spinal cord atrophy, neuroaxonal loss, and others. The major factor attributed to the market growth includes the rising prevalence of multiple sclerosis. According to the Multiple Sclerosis Trust, 2.5 million people globally were estimated to have multiple sclerosis in 2017. Adding to this, the treatment cost of multiple sclerosis has become an economic burden in many countries. According to the Institute for Clinical and Economic Review, the annual cost of treatment in the US is estimated to be $28,000 million. Hence, there is active government support for the treatment in terms of better healthcare spending, expert recommendations, and drug approvals.

Moreover, the shift in the preference towards oral drugs, the launch of new pipeline products, the rising need for better multiple sclerosis treatments, and rising government initiatives are expected to fulfill the market prospects during the forecast period. The robust range of upcoming pipeline drugs for the treatment is an opportunity for the market. Moreover, according to the study of McKenzie et al at the University of Dundee, the number of people with multiple sclerosis in the UK is growing by around 2.4% per year. All these factors are likely to augment the multiple sclerosis drugs market.

Some key players operating in the market include Biogen Ltd., F. Hoffman La-Roche AG, and Novartis International AG, among others. The market players are focusing on new product launches, mergers and acquisitions, and partnerships and collaborations. For instance, in March 2021, Johnson & Johnson declared that it will launch its newly approved drug for adults with relapsing multiple sclerosis (MS) in the US in early April 2021 at a similar price point to rival treatments. With the approval, the drugmaker enters a market currently dominated by major players, such as Novartis’ Kesimpta and Gilenya, Roche’s Ocrevus, and Biogen’s top-selling drug Tecfidera.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-

• By Drug Class
• By Route of Administration

• Regions covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape: Biogen Ltd., F. Hoffman La-Roche AG, and Novartis International AG, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

• Deviation from the pre-COVID-19 forecast
• Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Multiple Sclerosis Drugs Market Report by Segment

By Drug Class

• Immunomodulators
• Immunosuppressants
• Interferons

By Route of Administration

• Parenteral
• Oral

Global Multiple Sclerosis Drugs Market Report by Region

North America

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa